CartiHeal Ltd.
http://www.cartiheal.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From CartiHeal Ltd.
Deal Watch: Graphite Exits Via Reverse Merger With Presbyopia Specialist LENZ
Plus deals involving Abliva/Owl, Selecta/Cartesian, Novo Nordisk/Genevant, AbbVie/Aldeyra and more.
Orasis Prepares To Battle AbbVie In Presbyopia
The privately held firm got FDA approval for Qlosi, which like AbbVie’s Vuity is a low-dose formulation of pilocarpine for age-related near vision loss. Launch is planned for early 2024.
Minute Insight: Bioventus Completes Cartiheal Acquisition Following Agili-C Approval
Bioventus exercised a “call option” to acquire Cartiheal for about $315m, plus up to $135m in milestones. The US FDA recently approved Cartiheal’s Agili-C implant to treat knee joint surface lesions.
Market Brief: Global Orthobiologics Market Will Reach $2.3Bn By 2023 With Highest Growth In Cartilage Replacement
The global market for orthobiologics for musculoskeletal soft tissue replacement and regeneration is expected to reach $2.3bn by 2023, according to a new report by Informa's Meddevicetracker. This highly competitive market, which is led by Arthrex and other large and smaller players, continues to grow amid the rising prevalence of musculoskeletal soft tissue injuries and osteoarthritis. High prices of implants, the limited availability of donated tissue and limited reimbursement for synthetic scaffolds are limiting growth in this market.
Company Information
- Industry
-
Medical Devices
- Implantable Devices
- Other Names / Subsidiaries
-
- Bioventus Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice